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Abstract
Background: Alpha-2-antiplasmin (α2AP) is the main natural inhibitor of plasmin. The 
C-terminus of α2AP is crucial for the initial interaction with plasmin(ogen) and the rapid 
inhibitory mechanism. Approximately 35% of circulating α2AP has lost its C-terminus 
(non-plasminogen binding α2AP/NPB-α2AP) and thereby its rapid inhibitory capacity. 
The C-terminal cleavage site of α2AP is still unknown. A commercially available mono-
clonal antibody against α2AP (TC 3AP) detects intact but not NPB-α2AP, suggesting 
that the cleavage site is located N-terminally from the epitope of TC 3AP.
Objectives: To determine the epitope of TC 3AP and then to localize the C-terminal 
cleavage site of α2AP.
Methods: For epitope mapping of TC 3AP, commercially available plasma purified α2AP 
was enzymatically digested with Asp-N, Glu-C, or Lys-N. The resulting peptides were 
immunoprecipitated using TC 3AP-loaded Dynabeads® Protein G. Bound peptides 
were eluted and analyzed by liquid chromatography-tandem mass spectometry (LC-
MS/MS). To localize the C-terminal cleavage site precisely, α2AP (intact and NPB) was 
purified from plasma and analyzed by LC-MS/MS after enzymatic digestion with Arg-C.
Results: We localized the epitope of TC 3AP between amino acid residues Asp428 
and Gly439. LC-MS/MS data from plasma purified α2AP showed that NPB-α2AP 
results from cleavage at Gln421-Asp422 as preferred site, but also after Leu417, 
Glu419, Gln420, or Asp422.
Conclusions: The C-terminal cleavage site of human α2AP is located N-terminally 
from the TC 3AP epitope. Because C-terminal cleavage of α2AP can occur after multi-
ple residues, different proteases may be responsible for the generation of NPB-α2AP.
K E Y W O R D S
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1  | INTRODUC TION
Alpha-2-antiplasmin (α2AP) is the main natural inhibitor of the fi-
brinolytic enzyme plasmin.1-3
Native α2AP is produced by the liver and circulates in blood as an 
approximately 67-kDa single-chain glycoprotein of 464 amino acid 
residues, containing 11% to 14% carbohydrate.2,4,5 α2AP possesses 
unique N- and C-terminal ends, as we extensively reviewed.6 The 
N-terminus is involved in α2AP incorporation into a blood clot by ac-
tivated factor XIII-mediated crosslinking.7,8 The C-terminus is crucial 
for the initial interaction of α2AP with plasmin(ogen).9 α2AP contains 
six lysine residues at its C-terminus, which are involved in the interac-
tion with lysine binding sites in plasminogen.9,10 Based on the inter-
action with these lysine binding sites, two molecular species of α2AP 
have been described in plasma.11 One molecular form is able to bind 
to plasminogen (plasminogen binding α2AP, PB-α2AP), comprises ap-
proximately 65% of circulating α2AP, and is a fast-acting inhibitor of 
plasmin by rapidly forming plasmin-antiplasmin complexes. The other 
molecular form, which comprises approximately 35% of circulating 
α2AP, does not bind to plasminogen (non-plasminogen binding α2AP, 
NPB-α2AP) and inhibits plasmin at a much slower rate.11,12 Kluft and 
Los demonstrated the presence of the two variants in plasma and 
in serum by modified crossed immunoelectrophoresis.13 They also 
showed that only PB-α2AP is produced in the liver and that NPB-
α2AP is the result of posttranslational modification in the circula-
tion.14 Furthermore, it was reported that the NPB-α2AP fraction in 
plasma may contain some inactive or inactivated inhibitor.11,15
In addition to the main form of NPB-α2AP in vivo, it was shown 
that purified PB-α2AP can spontaneously convert into an NPB-α2AP 
form in vitro.16 Sasaki et al17 treated both purified PB-α2AP and in vitro 
formed NPB-α2AP after acetamidination with trypsin and analyzed 
the peptides by HPLC. A peptide representing the 26 C-terminal amino 
acids of the molecule was found in PB-α2AP, which was not present 
in NPB-α2AP formed in vitro. This indicated the participation of this 
C-terminal part in plasminogen binding. Some subsequent papers have 
mistakenly considered this trypsin cleavage site as the position where 
PB-α2AP is truncated into NPB-α2AP.18,19 The study by Sasaki et al only 
showed that NPB-α2AP is formed in vitro after a cleavage of a peptide 
smaller than 26 amino acid residues. To date, it is unknown where and 
how the conversion happens in the circulation. An actual in vivo cleav-
age site and a protease responsible have not yet been identified.
Leebeek et al20 have suggested that the in vivo and in vitro con-
versions of PB- α2AP to NPB-α2AP in plasma may have different 
mechanisms and possibly involve different cleavage sites. Using a 
commercially available monoclonal antibody against the C-terminus 
of α2AP (TC 3AP21) in a crossed immunoelectrophoresis technique, 
they showed that NPB-α2AP formed in vivo lost its capacity to bind 
to both plasminogen and the antibody, whereas NPB-α2AP formed in 
vitro lost the plasminogen binding capacity, but could still bind to the 
antibody. This indicated that in vivo and in vitro generated NPB-α2AP 
are not the same molecules but may differ in their C termini or may 
be structurally different. We reckoned that the epitope recognized by 
TC 3AP in the α2AP protein can be used to obtain a crude localization 
of the in vivo C-terminal cleavage site of α2AP; therefore, this study 
aimed to determine the epitope of TC 3AP and subsequently localize 
the C-terminal cleavage site of α2AP by mass spectrometry.
2  | METHODS
2.1 | Materials
Pooled normal plasma was prepared from citrated apheresis plasma 
(Sanquin blood bank, Rotterdam, The Netherlands) of five healthy 
donors. Commercially available plasma-purified α2AP (Calbiochem) 
was purchased from Merck Millipore. The mouse monoclonal an-
tibody against the C-terminus of α2AP (TC 3AP) was purchased 
from Technoclone. The custom made polyclonal rabbit Asn-α2AP 
antibody (anti-Asn-α2AP, affinity purified IgG) was raised against a 
peptide corresponding to amino acids Gln14 to Pro30 of the α2AP 
protein (Charles River Laboratories, Squarix GmbH) and has been 
used previously.22 The polyclonal goat total α2AP antibody (affinity 
purified IgG) (anti-total α2AP) directed to all forms of α2AP and the 
horseradish peroxidase-conjugated anti-total α2AP antibody were 
purchased from Affinity Biologicals. Cyanogen bromide-activated-
Sepharose® 4B was purchased from GE Healthcare. SigmaFASTTM 
Protease Inhibitor Cocktail, ammonium bicarbonate, 2-chloroacet-
amide, 1,4-dithiothreitol (DTT), and 3,3′,5,5′-tetramethylbenzidine 
were purchased from Sigma-Aldrich. Magnetic Dynabeads® Protein 
G, GelCode® Blue Stain Reagent, and endoproteinase Glu-C were 
purchased from Thermo Fisher Scientific. Endoproteinase Arg-C 
was purchased from Protea. Endoproteinase Asp-N was obtained 
from Roche. Endoproteinase Lys-N was purchased from U-Protein 
Express BV. XT Sample Buffer, XT reducing agent, and precast XT 
Criterion 10% polyacrylamide gels were purchased from BioRad.
2.2 | Epitope mapping of antibody TC 3AP
Epitope mapping of TC 3AP was carried out according to an adapted 
epitope extraction method as described previously.23,24 In detail, 
commercially available plasma-purified α2AP, lyophilized in buffer 
(200 mmol/L NaCl, 20 mmol/L Bis-Tris, pH 6.4), was resuspended in 
Essentials
• Due to proteolytic cleavage, part of circulating a2-anti-
plasmin (α2AP) loses the C-terminus.
• C-terminally cleaved α2AP is unable to inhibit plasmin 
rapidly.
• We found that C-terminal cleavage of α2AP occurs be-
tween residues Leu417 and Asp422.
• Our study gives more insight into the regulation of 
C-terminal heterogeneity of α2AP.
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distilled water followed by addition of Tris-HCl (pH 8.5) (50 mmol/L 
final concentration). Reduction and alkylation of α2AP was carried 
out by adding DTT (5 mmol/L final concentration), followed by incu-
bation for 30 minutes at 50°C under constant motion. Next, 2-chlo-
roacetamide was added (10 mmol/L final concentration) followed by 
incubation for 30 minutes at room temperature (RT) in the dark. The 
reaction was quenched by the addition of extra DTT (2.5 mmol/L 
final concentration), followed by digestion of α2AP with Asp-N, 
Glu-C, or Lys-N. A 1:20 final ratio (w/w) of Asp-N or Glu-C with 
α2AP, and a 1:1 final ratio of Lys-N with α2AP was used (buffers: 
50 mmol/L Tris-HCl, 1 mmol/L CaCl2, pH 8.5 for Asp-N; 50 mmol/L 
Tris-HCl, pH 8.5 for Glu-C; 100 mmol/L Tris-HCl, 1 mmol/L CaCl2, 
pH 10 for Lys-N). The mixtures were incubated overnight at 30°C. 
The digestion reactions were terminated by boiling the mixtures for 
10 minutes at 95°C.
After enzymatic digestion, α2AP peptides containing the epitope 
were purified from the mixtures by immunoprecipitation with TC 
3AP coupled magnetic Dynabeads® Protein G. The coupling proce-
dure was carried out by diluting 20 µg TC 3AP with phosphate-buff-
ered saline with Tween (PBST; 137 mmol/L NaCl, 2.7 mmol/L KCl, 
6.5 mmol/L Na2HPO4, 1 mmol/L KH2PO4, 0.02% Tween-20, pH 7.4), 
followed by incubation of the diluted antibody solution with 3 mg 
magnetic Dynabeads® Protein G for 1 hour at 4°C under constant 
motion. The beads were separated from the solution using a magnet, 
followed by removal of the supernatant. The beads were washed 
with PBST, mixed with the digested α2AP, and incubated overnight 
at 4°C under constant motion. After three stringent wash steps with 
PBST and five wash steps with phosphate buffered saline (PBS), 
bound α2AP peptides were eluted from the beads using 100 mmol/L 
glycine buffer (pH 2.2) during incubation for 1 hour at RT under con-
stant motion. Eluted peptides were collected, desalted using ZipTip 
C18 according to the manufacturer's instructions, dried, and ana-
lyzed by liquid chromatography-tandem mass spectrometry.
2.3 | Purification of α2AP
For the localization of the C-terminal cleavage site, PB- and 
NPB-α2AP were purified from normal pooled plasma by affinity 
chromatography. Briefly, 1 mg anti-total α2AP was coupled to 1 mL 
cyanogen bromide-activated-Sepharose® 4B. Normal pooled plasma 
(6 mL) was diluted with 6 mL wash buffer (0.1 mol/L Tris-HCl, 0.1% 
Tween-20, 1 mol/L NaCl, pH 8.1). To prevent nonspecific cleavages 
in α2AP, Protease Inhibitor solution was added to the diluted plasma 
sample, wash buffer and elution buffer (100 mmol/L glycine, 0.01% 
Tween-20, 0.1 mol/L NaCl, pH 2.2). The diluted plasma sample was 
incubated overnight with the anti α2AP-IgG-Sepharose 4B gel at 4°C 
with gentle stirring. After incubation, the gel was washed four times 
with wash buffer and placed in a column. α2AP was eluted with 4 mL 
elution buffer. The eluted fractions were neutralized with 1 mol/L 
Tris-HCl, pH 9.0.
The α2AP concentration of the eluted fractions was deter-
mined by ELISA. 96-Well microtiter plates (Nunc A/S, Roskilde, 
Denmark) were coated with 2 µg/mL (110 µL well-1 in 0.05 mol/L 
carbonate buffer, pH 9.6) anti-total α2AP antibody overnight at 4°C. 
Nonspecific sites were blocked with 200 µL 1% BSA in PBS contain-
ing 0.002% Tween-20 for 1 hour at RT and plates were washed once 
with PBS/0.002% Tween-20. Subsequently, eluted fractions were 
diluted 40 times and serial dilutions were made of normal pooled 
plasma (1:200-1:12 800) for the standard curve. Plates were incu-
bated for 2 hours at RT followed by four rounds of washing with 
PBS/0.002% Tween-20. Next, a horseradish peroxidase-conjugated 
anti-total α2AP antibody (1:2000) was added and incubated for 
1 hour at RT. After four wash steps with PBS/0.002% Tween-20, 
enzyme activity was determined using 3,3′,5,5′-tetramethylbenzi-
dine as substrate and the reaction was stopped after 10 minutes by 
adding 100 µL/well of 1 mol/L H2SO4. The absorbance was read at 
450 nm on a Victor3 1420 Multilabel Plate Counter (Perkin Elmer).
The eluted fractions with the highest α2AP concentrations were 
pooled and dialyzed against distilled water. Finally, the dialyzed 
pooled sample was dried by a SpeedVac procedure and resuspended 
in 60 µL distilled water.
2.4 | SDS-PAGE and Western blotting
To separate PB-α2AP and NPB-α2AP, 5 µg (for SDS-PAGE) and 
300 ng (for Western blot analyses) affinity-purified α2AP in 
TA B L E  1   Epitope mapping of antibody TC 3AP
Sequence Amino acids Frequency Mass m/z Dev Score
K.DFLQSLKGFPRG.D 428-439 11 1363.7248 455.5815 −1.57 39
K.DFLQSLKGFPRG.D - - - 682.8696 −0.18 51
Q.DSPGNKDFLQSLKGFPRG.D 422-439 12 1961.9959 491.5056 −1.44 41
Q.DSPGNKDFLQSLKGFPRG.D - - - 655.0053 −1.02 57
Q.DSPGNKDFLQSLKGFPRG.D - - - 982.0041 −1.11 61
Notes: Dev, the difference between the observed and calculated mass (in ppm); frequency, the number of times a peptide is observed in the mass 
spectrometry analysis; mass: the theoretical monoisotopic mass of the neutral peptide (in Daltons); m/z, the observed mass/charge; score, the ions 
score given to the peptide.
Peptides identified by Mascot analysis in the immobilized TC 3AP-bound α2AP fraction produced by enzymatic digestion of α2AP with Asp-N. Best 
scoring spectra are reported.
4  |     ABDUL et AL.
Tris-buffered saline were boiled for 5 to 10 minutes at 95°C in the 
presence of XT Sample Buffer and XT reducing agent and resolved 
on a precast XT Criterion 10% polyacrylamide gel. After electro-
phoresis, the proteins were stained by Coomassie or transferred 
to a nitrocellulose membrane using a PowerPac™ HC power sup-
ply (BioRad, Richmond, CA) with transfer buffer (25 mmol/L Tris, 
192 mmol/L glycine [pH 8.3], and 20% methanol) at 100V for 1 hour. 
After protein transfer, nonspecific sites on the nitrocellulose mem-
brane were blocked with 5% milk in PBS, pH 7.4, followed by three 
wash steps with PBS/0.1% Tween-20. Postblocking, the blot was 
incubated with a mixture of TC 3AP (1 mg/mL, 1:5000) and anti-
Asn-α2AP (1 mg/mL, 1:5000) in PBS/0.1% Tween-20 overnight at 
4°C under constant motion. After three wash steps, IRDye® 680CW 
donkey anti-mouse secondary antibody and IRDye® 800CW don-
key anti-rabbit secondary antibody were used for detection of TC 
3AP and the anti-Asn-α2AP antibody, respectively. After incubation 
for 1 hour at RT, three wash steps were performed and the blot was 
scanned in the 680- or 800-nm channel of an Odyssey® Imaging 
System (Lincoln, NE).
2.5 | Mass spectrometry for epitope mapping and 
C-terminal cleavage site analysis
For epitope mapping, the dried peptides containing the TC 3AP 
epitope were dissolved in 3% acetonitrile (ACN) with 0.5% formic 
acid (FA) and briefly sonicated. A fraction was injected onto a Waters 
nanoAcquity LC equipped with a Waters 20 mm x 180 µm nanoAC-
QUITY UPLC Symmetry C18 Trap Column with 5-µm particles and a 
homemade 40 cm x 75 µm fused silica analytical column with Waters 
3.5-µm XBridge BEH C18 particles. Peptides were separated using 
a 60-minute gradient from 99%A/1%B to 65%A/35%B (A = 0.1% 
FA, B = 0.1% FA in ACN) at 0.3 µL/min and 50°C and analyzed on a 
Thermo Orbitrap Fusion mass spectrometer in positive mode using a 
nanoESI source and a top speed method with 3 seconds’ cycle time 
and HCD/ETD fragmentation, full scan detection at 120K resolution 
in the orbitrap, and fragment ion detection in the ion trap.
Peak lists were automatically created from raw data files using 
the Mascot Distiller software (version 2.3; MatrixScience). The 
Mascot algorithm was used for searching against a UniProt database 
(release 2015_03.fasta or newer, taxonomy: Homo sapiens). The 
peptide tolerance was set to 10 ppm and the fragment ion tolerance 
was set to 0.8 Da for fragmentation spectra. A maximum number of 
two missed cleavages were allowed. Carbamidomethylated cysteine 
was set as fixed modification and oxidized methionine and deami-
dated asparagine and glutamine were set as variable modifications.
Data were additionally analyzed with Proteome Discoverer (ver-
sion 1.4; Thermo Scientific) and MaxQuant (version 1.5.2.8) using 
similar settings25 and appropriate digestion modes. For MaxQuant 
a false discovery rate of 0.01 for proteins and peptides and a min-
imum peptide length of seven amino acids were required. The tan-
dem mass spectometry spectra were searched against the UniProt 
database concatenated with the reversed versions of all sequences.
For C-terminal cleavage site analysis, a pilot experiment was 
performed in which gel bands corresponding to PB-α2AP and 
NPB-α2AP were cut from the gel, divided into equal parts, and de-
stained, reduced/alkylated, and dehydrated. The protein bands were 
subjected to overnight in-gel digestion at RT using 0.25 µg Arg-C 
in 50 mmol/L ammonium bicarbonate, 1 mmol/L CaCl2 1 mmol/L 
DTT pH 8, 0.05 µg Asp-N in 50 mmol/L Tris-HCl 1mM CaCl2 pH 
8, 0.1 µg Lys-C in 25 mmol/L Tris-HCl pH 8.5, or 0.2 µg trypsin in 
50 mmol/L ammonium bicarbonate 1 mmol/L CaCl2 pH 8.0. Peptides 
were extracted from the gel with 30% ACN 0.5% FA and mixing for 
30 minutes in a shaker followed by sonication in a water bath for 
2 minutes. The extracts were dried in a SpeedVac and the residues 
were redissolved in 3% ACN 0.5% FA and desalted with a ZipTip C18 
according to the manufacturer's instructions. The final eluates were 
dried in a SpeedVac and redissolved in 3% ACN 0.5% FA and soni-
cated briefly. Aliquots were injected into the mass spectrometer as 
described previously.
After the pilot experiment, the C-terminal cleavage site analysis 
was repeated under optimized conditions in which bands on gel were 
quantified using a BioRad GS-900 Calibrated Densitometer and the 
NPB-α2AP band, calculated at 1 ug protein, was cut from the gel 
and pretreated as described previously. Protein was in-gel digested 
at 30°C overnight with 0.5 µg Arg-C in 50 mmol/L ammonium bi-
carbonate, 5 mmol/L CaCl2, and 5 mmol/L DTT. Peptides were ex-
tracted, desalted, dried, and redissolved as described. An aliquot 
was injected onto a Thermo Scientific Easy-nLC 1200 equipped 
with a homemade 40 cm x 75 µm fused silica analytical column 
with Waters 3.5 µm XBridge BEH C18 particles without trapping 
column. Peptides were separated using a 60-minute gradient from 
99%A/1%B to 50%A/50%B (A = 0.1% FA, B = 0.1% FA in 80% ACN) 
at 0.3 µL/min and 50°C and analyzed on a Thermo Orbitrap Fusion 
Lumos Tribrid mass spectrometer in positive mode using a nanoESI 
source and a top speed method with 3 seconds’ cycle time and HCD/
F I G U R E  1   In-house purified α2AP visualized by SDS-PAGE 
and Western blot. (A) SDS-gel of purified α2AP. (B) Immunoblot 
obtained with anti-Asn-α2AP. (C) Immunoblot obtained with TC 
3AP. (D) Merged anti-Asn-α2AP and TC 3AP blots. The relative 
migration distances of molecular weight marker proteins are 
indicated on the left. PB-α2AP is indicated by arrowhead. NPB-
α2AP is indicated by an asterisk, as well as by a red box in (A)
kDa A B
*
* *
C D
250
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EThcD fragmentation, full scan detection at 60K resolution in the 
orbitrap, and fragment ion detection in the ion trap. Expected NPB-
α2AP C-terminal peptide masses, based on results from the pilot ex-
periment, were calculated assuming charge states 2+ and 3+, up to 4 
deamidations and up to 1 missed cleavage using sequences ELKEQQ, 
ELKEQQD, NPNSAPRELKEQQ, and NPNSAPRELKEQQD. These in 
total 26 m/z masses were favored for MS2 fragmentation by HCD and 
EThcD over other masses using an AGC target of 1E4 and increased 
injection times of 200 ms versus 50 ms for other masses (Table S1).
Data were analyzed with Mascot and MaxQuant (version 1.5.4.1) 
using similar settings as described and searched against the UniProt 
human database supplemented with truncated versions of α2AP 
(UniProt identifier P08697-1) starting from amino acid 300 up to 
491 and concatenated with the reversed versions of all sequences. 
Numbering of α2AP amino acids was according to methionine in po-
sition 1.
3  | RESULTS
3.1 | Epitope mapping of antibody TC 3AP
To obtain a crude localization of the α2AP C-terminal cleavage site, 
we first determined the epitope of TC 3AP. Because this antibody 
does not react with NPB-α2AP, we hypothesized that the in vivo 
cleavage site is located N-terminally from the TC 3AP epitope. The 
MS data of the Asp-N digest identified two peptides that were bound 
to immobilized TC 3AP and that should contain the epitope of TC 
3AP: Asp428-Gly439 (ions score: 39 and 51) and Asp422-Gly439 
(ions score: 41, 57 and 61) (Table 1). Multiple ions scores were found 
for the same peptide, depending on their charge (2+, 3+, or 4+). The 
MS data of the Glu-C and Lys-N digests did not display any peptides, 
probably because of the presence of multiple protease specific cleav-
age sites in this region, resulting in small peptides that do not bind to 
immobilized TC 3AP or are undetectable by MS. Thus, we localized 
the epitope of TC 3AP to the region between Asp428 and Gly439.
3.2 | C-terminal cleavage site analysis
SDS-PAGE of the affinity purified α2AP showed protein bands with 
molecular weights between 50 and 67 kDa (Figure 1A). Western blot 
analyses showed reactivity of the anti-Asn-α2AP antibody to appar-
ently two bands with molecular weights of approximately 60 kDa 
and 67 kDa (Figure 1B). Multiple protein bands within the 60- to 67-
kDa range showed reactivity with TC 3AP (Figure 1C), indicating the 
presence of the C-terminus. However, there was one protein band at 
approximately 63 kDa that did not react with TC 3AP, suggesting the 
absence of the C-terminus, thus representing NPB-α2AP (red band 
in Figure 1D). The two minor bands below the main band of PB-α2AP 
in Figure 1C could possibly explained by deglycosylation, truncation 
at the N-terminus, or by the presence of isoform 2 originating from 
alternative splicing (www.unipr ot.org). T
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Mascot analysis data from the pilot experiment with Arg-C dis-
played one peptide (Asn408-Gln421) in the NPB-α2AP protein band 
that did not end with the Arg-C specific amino acid residue argi-
nine (data not shown). This peptide was not present in PB-α2AP. 
Therefore, we hypothesized that this C-terminal end was already 
present in the purified α2AP sample and represents the in vivo 
cleavage site. The digestions with Asp-N, Lys-C, and trypsin did 
not result in any C-terminal ends that were not the result of pro-
tease specific cleavages. The experiment with Arg-C digestion of 
NPB-α2AP was repeated under optimized conditions to confirm the 
Gln421-Asp422 cleavage site. Mascot analysis data identified six 
peptides that could not be ascribed to the action of Arg-C: Asn408-
Leu417, Asn408-Glu419, Asn408-Gln420, Asn408-Gln421, deam-
idated Asn408-Gln421, and Asn408-Asp422 (Table 2). MaxQuant 
analysis data from the optimized experiment revealed four of 
these six peptides: Asn408-Gln420, Asn408-Gln421, deamidated 
Asn408-Gln421, and Asn408-Asp422 (Table 2; Figures S1-S6). In 
both analysis methods, the Asn408-Gln421 peptide displayed the 
highest ions scores and best spectra (Figure 2). Therefore, our data 
suggest that the Gln421-Asp422 is a preferred cleavage site in the 
C-terminus of α2AP.
Taken together, our results suggest that in vivo NPB-α2AP 
results from cleavage after Leu417, Glu419, Gln420, Gln421, or 
Asp422, with Gln421 as preferred cleavage site (Figure 3). As ex-
pected, the Leu417-Asp422 region is located N-terminally from the 
TC 3AP epitope, explaining why NPB-α2AP is not detected by TC 
3AP, as summarized in Figure 4.
4  | DISCUSSION
In this study, we determined the epitope of monoclonal antibody TC 
3AP, which detects PB-α2AP but not in vivo formed NPB-α2AP.20 
Supported by this information, we specified where PB-α2AP is trun-
cated in vivo for the generation of NPB-α2AP. We found that the 
TC 3AP epitope is located in a region between Asp428 and Gly439 
F I G U R E  2   MS/MS fragmentation spectra of the (A) nondeamidated and (B) deamidated Asn408-Gln421 peptide in an overnight Arg-C 
digest of NPB-α2AP as determined by Mascot and MaxQuant analysis, respectively. Best spectrum data are shown. The overlapping labels 
of the peaks between m/z 730 and 750 in (A) should be read as the following: b(13)++ m/z 731.3759; y0(13)++,y*(13)++, z + 1(13)**, m/z 
738.3837, 738.8757, 739.3796; y(13)++ m/z 747.3890
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in the α2AP C-terminus and that NPB-α2AP results from multiple 
cleavages in PB-α2AP that occur in a region between Leu417 and 
Asp422.
The region of the TC 3AP epitope overlaps the region recognized 
by a commercial polyclonal antibody directed to α2AP (EB08777, 
Everest Biotech Ltd.). This commercial antibody was raised against 
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the peptide Lys427-Lys441. This suggests, that this C-terminal re-
gion is highly immunogenic and strengthens the reliability of our 
found TC 3AP epitope.
We found that in vivo cleavage of PB-α2AP occurs between 
Leu417 and Asp422. In a previous study, Clemmensen et al described 
the purification of PB-α2AP from plasma.16 In that study, PB-α2AP 
(67 kDa) was spontaneously converted in vitro into two different 
forms with lower molecular weights (65 and 60 kDa). Native PB-α2AP 
was able to bind plasminogen and rapidly inactivate plasmin, whereas 
the 65-kDa form did not bind plasminogen but could still slowly in-
activate plasmin. The 60-kDa form neither bound plasminogen nor 
inactivated plasmin. In our study, we focused on in vivo-generated 
NPB-α2AP. This NPB-α2AP form still contains the reactive site, 
which is needed for plasmin inhibition. Our MS data revealed sev-
eral possible C-terminal cleavage sites, located C-terminally from the 
reactive site, indicating that the NPB-α2AP form still has inhibitory 
activity toward plasmin. Thus, although Sasaki et al showed that 
in vitro-generated 65 kDa NPB-α2AP lacks at most 26 amino acid 
residues (cleavage after Arg438),17 our MS data show that in vivo- 
generated NPB-α2AP lacks about 43 amino acid residues by cleavage 
in a region between Leu417 and Asp422. 
Leebeek et al20 described that NPB-α2AP formed in vivo lost 
its capacity to bind to both plasminogen and TC 3AP, which is in 
line with our MS data showing that NPB-α2AP formed in vivo is 
cleaved in a region between Leu417 and Asp422, which is located 
N-terminally from the TC 3AP epitope. Furthermore, they showed 
that NPB-α2AP formed in vitro lost its plasminogen binding capac-
ity, but could still bind to TC 3AP.20 This in vitro-formed NPB-α2AP 
might be similar to the 65-kDa form of NPB-α2AP described by 
Sasaki et al,17 which lacks at most 26 amino acid residues (Gly439-
Lys464), and still contains the TC 3AP epitope located in a region 
between Asp428 and Gly439.
Five potential cleavage sites located in close proximity of each 
other were obtained from MS data, indicating the possibility of 
multiple NPB-α2AP forms and suggesting the presence of a pro-
teolytic sensitive region (Figure 4). This makes the possibility of 
NPB-α2AP being the result of cleavage by one specific regulating 
protease unlikely. However, the highest ions scores and best spec-
tra were found for the Asn408-Gln421 peptide. This peptide was 
also prominently found in the pilot experiment, suggesting that 
the Gln421-Asp422 is a preferred cleavage site. The Peptidase 
Database MEROPS (release 12.1) contains 33 enzymes capable of 
cleaving Gln-Asp bonds and might be helpful for finding candidate 
enzymes.
An alternative explanation for the five potential cleavage sites is 
that PB-α2AP is cleaved by one endopeptidase at Asp422-Ser423 
and further truncated by different carboxypeptidases, such as 
thrombin-activatable fibrinolysis inhibitor and carboxypeptidase 
N. It is, however, unknown whether all required carboxypeptidases 
exist in plasma. Mutagenesis of α2AP could be useful to further 
study the cleavage region.
To date, there is no three-dimensional protein structure avail-
able for the complete C-terminus of α2AP, because of its flexi-
bility.26 Law et al26 showed that the first 10 amino acids of the 
C-terminus of α2AP (Asn410-Glu419) are tightly associated with 
the serpin body, because residues 416 and 417 are incorporated 
in β-sheet C. The remainder of the C-terminus (Gln420-Lys464) 
could not be modeled into electron density. The C-terminal cleav-
age sites described in the current study are situated between 
Leu417 and Asp422, which are located in the beginning of the 
flexible C-terminus (Figure 3). Therefore, it is plausible that the 
found C-terminal cleavage sites are located in a region sensitive 
for proteolysis.
To conclude, we mapped the epitope of antibody TC 3AP and 
localized the in vivo C-terminal cleavage sites of PB-α2AP. These 
results can be used to gain more insight into the regulation of 
C-terminal heterogeneity of α2AP and thus the regulation of the fi-
brinolytic system.
F I G U R E  3   Three-dimensional structure of human α2AP as 
predicted by I-TASSER.27 Red, β-sheet A; green, β-sheet B; yellow, 
β-sheet C; magenta, reactive center loop; cyan, C-terminal cleavage 
area Leu417-Asp422 (LKEQQD); blue, C-terminus; orange, epitope 
of TC 3AP. Left panel: front view. Right panel: side view, 90°C 
clockwise rotation
Cleavage area
Leu417-Asp422
F I G U R E  4   Schematic representation of the α2AP C-terminus from Asn408 to Lys464. Arrows indicate the in vivo C-terminal cleavage 
sites (preferred site between Gln421 and Asp422), the bold underlined sequence represents the area that includes the TC 3AP epitope, and 
the brace indicates the area that includes the in vitro C-terminal cleavage site as described by Sasaki et al.17
408 464
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